Assessment of growth hormone status in acromegaly: What biochemical markers to measure and how?

Growth Hormone and IGF Research

Volumn 10, Issue SUPPL. B, 2000, Pages

  Camacho Hubner C ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Biochemical marker; Growth hormone; Insulin like growth factor I; Insulin like growth factor binding proteins

Indexed keywords

GLUCOSE; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ACROMEGALY; CONCENTRATION RESPONSE; FOLLOW UP; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROVOCATION TEST; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 0033869362     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(00)80024-6     Document Type: Review

References (37)

1. Normal and aberrant growth
2. Disorders of growth hormone and insulin-like growth factor secretion and action
3. Effects of recombinant human insulin-like growth factor (IGF)-I therapy in a patient with a partial IGF-I gene deletion
4. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children
5. Diagnosis of growth hormone deficiency in adults
6. Monitoring of growth hormone replacement therapy in adults based on measurement of serum markers
7. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
8. Acromegaly
9. Insulin-like growth factors and their binding proteins: Biological actions
10. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary
11. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
12. The 'binding protein' binding protein: Clinical application of acid labile subunit (ALS) measurement
13. Insulin-like growth factor (IGF)-binding protein-5 forms an alternative ternary complex with IGFs and the acid-labile subunit
14. How much insulin-like growth factor-I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy
15. Valid measurements of total IGF concentrations in biological fluids. Recommendations from the 3rd International Symposium on Insulin-like Growth Factors
16. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults
17. Physiological regulation of growth hormone secretion-insulin-like growth factor-I axis: Predominant impact of age, obesity, gonadal function, and sleep
18. Contrasting effects of oral and transdermal routes of oestrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor-I and GH binding protein in post-menopausal women
19. Somatomedin response to testosterone stimulation in male pseudohermaphroditism, cryptorchidism, anorchia, or micropenis
20. Hyperprolactinemia is associated with increased immunoreactive and bioactive Somatomedin C in hypopituitarism
21. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I
22. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine
23. Current treatment guidelines for acromegaly
24. Acromegaly: Diagnosis and therapy
25. Evaluation of acromegaly by radioimmunoassay of somatomedin-C
26. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly
27. Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults
28. Plasma insulin-like growth factor-I/Somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
29. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women
30. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay
31. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly
32. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly
33. Treatment of acromegaly with B2036-PEG, a growth hormone receptor antagonist
34. Expression of insulin-like growth factor binding protein (IGFBP)-2, IGFBP-3 and p53 in patients with colonic neoplasia
35. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients
36. Alterations in serum levels of insulin-like growth factors and insulin-like growth factor binding proteins in patients with colorectal cancer
37. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor